Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05771480 · ClinicalTrials.gov registry record · Phase 3
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT05771480: Active Phase 3 study of Biliary Tract Cancer, sponsored by AstraZeneca.
NCT05771480 is a Phase 3 study of Biliary Tract Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 142 participants, below the 235-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05771480, a Phase 3 study of Biliary Tract Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
Primary Outcome
PRAE is defined as an AE which has been assessed by the investigator to be possibly related to IMP.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- DRUG Gemcitabine + cisplatin
- DRUG Gemcitabine + carboplatin
- DRUG Gemcitabine monotherapy
- DRUG Gemcitabine + oxaliplatin
Study Locations (20)
Other
- Research Site - Clichy
- Research Site - Dijon
- Research Site - Montpellier
- Research Site - Villejuif
- Research Site - Chemnitz
- Research Site - Hanover
- Research Site - Castelfranco Veneto
- Research Site - Foggia
- Research Site - Palermo
- Research Site - Pisa
- Research Site - Rozzano
- Research Site - Chūōku
- Research Site - Kanazawa
- Research Site - Kashiwa
- Research Site - Kyoto
- Research Site - Osaka
Alabama
- Research Site - Mobile
California
- Research Site - Orange
District of Columbia
- Research Site - Washington D.C.
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2023-08-16 |
| Est. Completion | 2026-03-17 |
| Phase | Phase 3 |
What the registry record for NCT05771480 still lists
NCT05771480 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 235-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Biliary Tract Cancer appearing as the primary indexed condition, and to 5 interventions - of which Durvalumab is the first listed.
NCT05771480 names 20 study sites across 5 states, led by Other, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05771480 about?
NCT05771480 is a clinical study titled "Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)". A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
What is the current status of trial NCT05771480?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2023-08-16. Estimated completion is 2026-03-17.
What conditions does trial NCT05771480 study?
This clinical trial studies the following conditions: Biliary Tract Cancer.
What interventions are being tested in trial NCT05771480?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Gemcitabine + cisplatin (DRUG), Gemcitabine + carboplatin (DRUG), Gemcitabine monotherapy (DRUG), Gemcitabine + oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT05771480?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05771480 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05771480's enrollment target sits among peer trials
142 16th of 36 higher than 21 of 36 other Biliary Tract Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Tract Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RECRUITING · Phase 3
-
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RECRUITING · Phase 3
-
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
RECRUITING · Phase 3
-
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI